Skip to main content
Erschienen in: Virchows Archiv 1/2019

06.09.2018 | Brief Report

Novel KHDRBS1-NTRK3 rearrangement in a congenital pediatric CD34-positive skin tumor: a case report

verfasst von: Matthias Tallegas, Sylvie Fraitag, Aurélien Binet, Daniel Orbach, Anne Jourdain, Stéphanie Reynaud, Gaëlle Pierron, Marie-Christine Machet, Annabel Maruani

Erschienen in: Virchows Archiv | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Cutaneous spindle-cell neoplasms in adults as well as children represent a frequent dilemma for pathologists. Along this neoplasm spectrum, the differential diagnosis with CD34-positive proliferations can be challenging, particularly concerning neoplasms of fibrohistiocytic and fibroblastic lineages. In children, cutaneous and superficial soft-tissue neoplasms with CD34-positive spindle cells are associated with benign to intermediate malignancy potential and include lipofibromatosis, plaque-like CD34-positive dermal fibroma, fibroblastic connective tissue nevus, and congenital dermatofibrosarcoma protuberans. Molecular biology has been valuable in showing dermatofibrosarcoma protuberans and infantile fibrosarcoma that are characterized by COL1A1-PDGFB and ETV6-NTRK3 rearrangements respectively. We report a case of congenital CD34-positive dermohypodermal spindle-cell neoplasm occurring in a female infant and harboring a novel KHDRBS1-NTRK3 fusion. This tumor could belong to a new subgroup of pediatric cutaneous spindle-cell neoplasms, be an atypical presentation of a plaque-like CD34-positive dermal fibroma, of a fibroblastic connective tissue nevus, or represent a dermatofibrosarcoma protuberans with an alternative gene rearrangement.
Literatur
1.
Zurück zum Zitat Kutzner H, Mentzel T, Palmedo G et al (2010) Plaque-like CD34-positive dermal fibroma (“medallion-like dermal dendrocyte hamartoma”): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans. Am J Surg Pathol 34:190–201CrossRefPubMed Kutzner H, Mentzel T, Palmedo G et al (2010) Plaque-like CD34-positive dermal fibroma (“medallion-like dermal dendrocyte hamartoma”): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans. Am J Surg Pathol 34:190–201CrossRefPubMed
2.
Zurück zum Zitat Fletcher CDM (2013) WHO classification of tumours of soft tissue and bone. IARC Press Fletcher CDM (2013) WHO classification of tumours of soft tissue and bone. IARC Press
3.
Zurück zum Zitat Requena L (2014) Cutaneous soft tissue tumors, 1 edition. LWW, Philadelphia Requena L (2014) Cutaneous soft tissue tumors, 1 edition. LWW, Philadelphia
4.
Zurück zum Zitat de Feraudy S, Fletcher CDM (2012) Fibroblastic connective tissue nevus: a rare cutaneous lesion analyzed in a series of 25 cases. Am J Surg Pathol 36:1509–1515CrossRefPubMed de Feraudy S, Fletcher CDM (2012) Fibroblastic connective tissue nevus: a rare cutaneous lesion analyzed in a series of 25 cases. Am J Surg Pathol 36:1509–1515CrossRefPubMed
5.
Zurück zum Zitat Agaram NP, Zhang L, Sung Y-S et al (2016) Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. Am J Surg Pathol 40:1407–1416CrossRefPubMedPubMedCentral Agaram NP, Zhang L, Sung Y-S et al (2016) Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. Am J Surg Pathol 40:1407–1416CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Weinstein JM, Drolet BA, Esterly NB et al (2003) Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 139:207–211CrossRefPubMed Weinstein JM, Drolet BA, Esterly NB et al (2003) Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 139:207–211CrossRefPubMed
7.
Zurück zum Zitat Orbach D, Brennan B, De Paoli A, et al (2016) Conservative strategy in infantile fibrosarcoma is possible: the European paediatric soft tissue sarcoma study group experience. Eur J Cancer Oxf Engl 1990 57:1–9 Orbach D, Brennan B, De Paoli A, et al (2016) Conservative strategy in infantile fibrosarcoma is possible: the European paediatric soft tissue sarcoma study group experience. Eur J Cancer Oxf Engl 1990 57:1–9
8.
9.
Zurück zum Zitat Davis JL, Lockwood CM, Albert CM et al (2018) Infantile NTRK-associated mesenchymal tumors. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 21:68–78CrossRef Davis JL, Lockwood CM, Albert CM et al (2018) Infantile NTRK-associated mesenchymal tumors. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 21:68–78CrossRef
10.
Zurück zum Zitat Khotskaya YB, Holla VR, Farago AF et al (2017) Targeting TRK family proteins in cancer. Pharmacol Ther 173:58–66CrossRefPubMed Khotskaya YB, Holla VR, Farago AF et al (2017) Targeting TRK family proteins in cancer. Pharmacol Ther 173:58–66CrossRefPubMed
11.
Zurück zum Zitat Church AJ, Calicchio ML, Nardi V et al (2018) Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 31:463–473CrossRefPubMed Church AJ, Calicchio ML, Nardi V et al (2018) Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 31:463–473CrossRefPubMed
12.
Zurück zum Zitat Anderson J, Gibson S, Sebire NJ (2006) Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma. Histopathology 48:748–753CrossRefPubMed Anderson J, Gibson S, Sebire NJ (2006) Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma. Histopathology 48:748–753CrossRefPubMed
14.
Zurück zum Zitat Nagasubramanian R, Wei J, Gordon P et al (2016) Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer 63:1468–1470CrossRefPubMedPubMedCentral Nagasubramanian R, Wei J, Gordon P et al (2016) Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer 63:1468–1470CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Drilon A, Siena S, S-HI O et al (2017) Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor Entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7:400–409CrossRefPubMedPubMedCentral Drilon A, Siena S, S-HI O et al (2017) Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor Entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7:400–409CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Hechtman JF, Benayed R, Hyman DM et al (2017) Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 41:1547–1551CrossRefPubMedPubMedCentral Hechtman JF, Benayed R, Hyman DM et al (2017) Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 41:1547–1551CrossRefPubMedPubMedCentral
Metadaten
Titel
Novel KHDRBS1-NTRK3 rearrangement in a congenital pediatric CD34-positive skin tumor: a case report
verfasst von
Matthias Tallegas
Sylvie Fraitag
Aurélien Binet
Daniel Orbach
Anne Jourdain
Stéphanie Reynaud
Gaëlle Pierron
Marie-Christine Machet
Annabel Maruani
Publikationsdatum
06.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 1/2019
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-018-2415-0

Weitere Artikel der Ausgabe 1/2019

Virchows Archiv 1/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie